Catherine is a patent and regulatory Life sciences & health specialist with a degree in pathology. She is based in the London, Dublin, and Belfast offices.

Catherine's experience

  • Representing Accord in revocation proceedings before the UK Patents Court concerning a patent protecting a subcutaneous formulation of Herceptin (trastuzumab) the blockbuster breast cancer drug.

  • Advising global pharmaceutical companies on regulatory matters, including marketing authorisation filing for fixed-dose combination products, interpretation of the Centralised Procedure framework, and strategic carve outs of indications or safety features from applications due to patent rights.

  • On the record for Accord Healthcare in proceedings before the UK Patents Court, seeking revocation of a patent relating to the use of Janssen’s Stelara® (Ustekinumab) in the treatment of ulcerative colitis.

  • Representing Accord Healthcare, and Sandoz in proceedings before the Patents Court seeking revocation of Astellas’ patent protecting their highest value product, enzalutamide (Xtandi), used in the treatment of prostate cancer.

  • Advised Accord Healthcare Limited, a pharmaceutical company, on matters related to Dexmedetomidine Precedex® including representation as an intervener in proceedings before the General Court brought by Orion.

    • United Kingdom
  • Advising and representing, jointly, Sandoz AG, Sandoz Limited & Accord in revocation proceedings before the UK Patents Court in respect of a dosing regime patent concerning the product Rivaroxaban (Xarelto). If successful, the action will clear the way for generic rivaroxaban products to enter the UK market.

    • cross-border
  • Advised Samsung on its partnering with digital healthcare leader, Babylon, to power Samsung's Health App and "Ask an Expert" function. Advice included the application of the medical devices regulatory framework to the new digital health product.

  • Acted for Accord Healthcare in the High Court on the revocation of three patents relating to Celgene's blockbuster multiple myeloma product Revlimid.

  • Advised Teva on preparing judicial review pleadings about its generic medicinal product for the treatment of multiple sclerosis. The case sought to clarify the scope of the so called Global Marketing Authorisation and when an applicant is entitled to receive regulatory data exclusivity as a reward for developing medicinal products and follow-on medicinal products.

  • Advised Teva's challenge of Novartis in obtaining an extension to its SPC covering the medicinal product imatinib.

Credentials

  • 2017
    Joined Pinsent Masons
  • 2016
    Qualified - Ireland
  • 2015
    Olswang, Senior Associate
  • 2011
    Winston & Strawn, Associate
  • 2008
    Bristol University - Postgraduate Diploma in IP Law
  • 2007
    Qualified - England and Wales
  • 2007
    Taylor Wessing, Associate
  • 2005
    Nottingham Law School - Legal Practice Course
  • 2004
    Nottingham Law School - Graduate Diploma in Law
  • 2003
    University of Cambridge - MA(hons) Natural Sciences (Pathology)
Load More

Out-Law / Insight by Catherine Drew

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.